I, Working model for regulation of NPC progression and tumorigenesis by INSL5-GPCR142 axis. INSL5 is highly expressed in NPC tumor cells with poor prognosis in NPC patients. INSL5 can physically bind to the receptor GPCR142 to contribute to oncogenic function by reprogramming glycolysis, which is promoted by activation of the STAT5 signaling pathway. The anti-INSL5 neutralizing antibody, anti-GPCR142 neutralizing antibody and glycolysis inhibitor could be attractive approaches for sensitizing INSL5-overexpressing NPC tumor cells. 